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Heart rate (HR) variability has been extensively studied in patients surviving an acute
myocardial infarction (AMI). The majority of studies have shown that patients with reduced
or abnormal HR variability/turbulence have an increased risk of mortality within few years
after an AMI. Various measures of HR dynamics, such as time-domain, spectral, and
non-linear measures of HR variability, as well as HR turbulence, have been used in risk
stratiﬁcation of post-AMI patients. The prognostic power of various measures, except of
those reﬂecting rapid R–R interval oscillations, has been almost identical, albeit some
non-linear HR variability measures, such as short-term fractal scaling exponent, and HR
turbulence, have provided somewhat better prognostic information than the others. Abnormal HR variability predicts both sudden and non-sudden cardiac death after AMI. Because
of remodeling of the arrhythmia substrate after AMI, early measurement of HR variability to identify those at high risk should likely be repeated later in order to assess the
risk of fatal arrhythmia events. Future randomized trials using HR variability/turbulence as
one of the pre-deﬁned inclusion criteria will show whether routine measurement of HR
variability/turbulence will become a routine clinical tool for risk stratiﬁcation of post-AMI
patients.
Keywords: mortality, coronary artery disease, sudden cardiac death

The purpose of this mini-review is to discuss the role of measurement of heart rate (HR) variability in patients after an acute
myocardial infarction (AMI), especially its potential or proven
clinical utility, by itself or in combination with other variables.
Studies will be reviewed that employed a large variety of HR variability measures, with the majority derived from easily obtainable
24-h recordings.
Clinical utility is, of course, a broad concept. In this review,
we will consider a measure to have clinical utility, if it identiﬁes patients at higher risk of an adverse outcome, differentiates
those with more advanced from those with less advanced disease,
identiﬁes those who would beneﬁt from interventions or identiﬁes
those who are beneﬁting from or being harmed by an intervention.
HR variability has been applied in a huge number of studies. We
have chosen to limit our review to main studies focusing on clinical application of HR variability measurements from 24-h Holter
recordings in patients who have survived an AMI.

BACKGROUND FOR ABNORMAL HR VARIABILITY
Heart rate variability is a term that encompasses a large number of measures of different types that have been described in
details in other articles of this Special Topic of the journal. Timedomain measures reﬂect “how much” HRV there is. In general,
if such measures are extremely low, it can be assumed that there
is true autonomic dysfunction, but higher values for these various measures could reﬂect more healthy autonomic function or
an unhealthy, highly irregular HR pattern (erratic rhythm). Frequency domain measures have the same properties. Extremely
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low values are associated with a lack of autonomic modulation
of HR, but higher values, without examination of their underlying organization using power spectral plots or other graphical
methods, cannot be assumed to reﬂect better HR variability. Nonlinear measures like the short-term fractal scaling exponent and
the power–law slope, appear to better differentiate between healthy
and unhealthy organization of the heart’s rhythm and have proved
to be more sensitive for risk stratiﬁcation that some of the standard
measures (Bigger et al., 1996; Huikuri et al., 2000). HR turbulence, which was covered recently in detail (Bauer et al., 2008),
also appears to be sensitive to autonomic dysfunction, especially
to impaired baroreﬂex function. It is likely that the optimal characterization of normal and abnormal HR variability would be based
on a combination of these different HR variability parameters
rather than on a single one.

PROGNOSTIC SIGNIFICANCE OF HR VARIABILITY AFTER AMI
The prognostic signiﬁcance of HR variability has been extensively
studied in patients who have survived an AMI. Table 1 summarizes
the results of main studies assessing the prognostic signiﬁcance of
HR variability measurements from 24-h recordings. As early as
Wolf et al. (1978) showed that patients with a low magnitude of
short-term HR variability (no sinus arrhythmia on 30 consecutive R–R intervals on admitting ECG) had a poor prognosis after
AMI. In the late 1980s, the multicenter post-infarction project
(MPIP) conﬁrmed the predictive value of reduced HRV by measuring 24-h SD of N–N intervals (SDNN) over 24 h following AMI
(Kleiger et al., 1987). Adjustment for covariates did not explain
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Table 1 | Summary of main studies assessing the prognostic significance of heart rate variability after acute myocardial infarction.
Study

Kleiger et al. (1987)
Bigger et al. (1992)

HRV

Number of

Mean follow

Primary

measurement

patients

up time

endpoint

SDNN

808

34 months

Frequency

715

2.5 years

domain measures

Main results

Comment

All-cause

Increased mortality, if

Landmark study

mortality

SDNN < 50 ms

All-cause death,

All frequency domain

VLF spectral power was

cardiac death,

measures of HRV

the strongest predictor

arrhythmic death

predicted an increased

All-cause

All frequency domain

mortality

measures predicted the

performed 1 year after

risk of primary endpoint

AMI

risk of primary endpoint
Bigger et al. (1993)

Frequency

331

3 years

domain measures
Fei et al. (1996)

SDNN and HRV

700

1 year

index

All-cause

Geometric HRV index

mortality

predicted mortality

Holter recording were

better than SDNN
Bigger et al. (1996)

Power–law

715

3 years

behavior

Power–law regression

All-cause

Power–law regression

mortality

between log(power)

analyzed from ULF and

and log(frequency)

VLF spectral areas

predicted mortality
La Rovere et al. (1998)

Huikuri et al. (2000)

SDNN

Spectral, fractal

1284

446

21 months

685 days

and time-domain

Cardiac death and

SDNN < 70 ms

non-fatal cardiac

predicted increased

Multicenter study

arrest

cardiac mortality

All-cause

Short-term fractal

Post-AMI patients with

mortality

scaling exponent was

depressed ejection frac-

the most powerful

tion

measures

predictor of mortality
Mäkikallio et al. (2005)

Stein et al. (2005)

Sudden cardiac

All HRV measures

HRV predicted equally

and, time-domain

death,

predicted sudden and

both sudden and non-

measures

non-sudden

non-sudden cardiac

sudden cardiac death.

cardiac death

death

Largest HRV study

All-cause

Fractal measures

Short-term fractal scal-

mortality

predicted all-cause

ing exponent was more

mortality

powerful predictor than

Spectral, fractal

Spectral, fractal,

2130

740

1012 days

362 days

and time-domain
measures

other HRV measures
Perkiömäki et al. (2008)

Spectral, fractal

675

30 months

and time-domain

Non-fatal

Several measures of

coronary events

HRV predicted primary
endpoint

measures
Huikuri et al. (2009)

Spectral, fractal

312

2 years

and time-domain

ECG documental

Many HRV measures

VLF power was the

VT or VF

predicted the primary

strongest predictor

endpoint

measures
Erdogan et al. (2008)

SDNN

412

4.3 years

All-cause

SDNN < 50 ms

Positive predictive power

mortality

predicted mortality

of SDNN was low

AMI, acute myocardial infarction; ECG, electrocardiogram; HRV, heart rate variability; SDNN, SD of N–N intervals; ULF, ultra-low frequency; VF, ventricular ﬁbrillation;
VLF, very-low frequency; VT, ventricular tachycardia.

this association. Other studies (including a reanalysis of MPIP)
have shown that spectral measures of HR variability, mainly the
very-low and low frequency spectral components, are reduced in
survivors of AMI and that decreased values are associated with an
increased risk of all-cause mortality (Bigger et al., 1992).
Because accurate Holter scanning is relatively labor intensive,
the group at St. George’s hospital in London experimented with
global, geometric indices of HR variability (HR variability index)
that were derived from the histogram of N–N intervals (Malik
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et al., 1989). Decreased values for these measures were also found
to be associated with higher risk of mortality (Fei et al., 1996). In
addition, this group suggested that markedly reduced SDNN for
a single, stable 5-min period could pre-select patients in whom
24-h Holter recordings using geometric methods would provide
signiﬁcant risk stratiﬁcation.
The autonomic tone and reﬂexes after myocardial infarction
(ATRAMI) trial was a multicenter observational study performed
about 10 years after MPIP. The ATRAMI investigators conﬁrmed
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that reduced 24-h SDNN (<70 ms in this case) is associated with
an increased mortality during 21 months of follow up (La Rovere
et al., 1998). Furthermore, the combination of low SDNN and
left ventricular ejection fraction <35% carried a high risk of
mortality.
Early studies focused on measurement of HR variability relatively early after AMI. Measures of HR variability appeared to
be more depressed at the early phase of AMI with substantial
improvement during recovery (Jokinen et al., 2003). Despite this
autonomic recovery, measurement of HR variability has been
shown to yield similar prognostic information when the 24-h HRV
measurements were performed late after AMI (Bigger et al., 1993;
Jokinen et al., 2003).
The post-MI studies performed in the 1980s and 1990s used 24h time and frequency domain as well as geometric measures of HR
variability for risk stratiﬁcation of patients after AMI. Although
all statistical, geometrical, and spectral measures of HR variability
differ in their manner of computation and analysis, these methods
are fundamentally based on moment statistics and describe the
magnitude of HR variability or of its underlying components. It
is therefore not surprising that most of these measures that have
been shown to have prognostic value have relatively close mutual
correlation, and that there are only minor differences in prognostic power between them. It must be kept in mind though that
measures of beat-to-beat HR variability which are supposed to
reﬂect respiratory related vagal control of HR (HF power, pNN50,
rMSSD) have rarely shown a strong association with outcome.
This is likely because of the high prevalence of erratic rhythm in
these populations resulting in higher measures for these parameters that do not reﬂect better parasympathetic function. One study
showed that when erratic short-term R–R intervals was excluded
from the analysis, HR variability related to respiratory cycles predicted sudden cardiac death even better than the standard HR
variability indexes (Peltola et al., 2008).
More recent studies have applied methods based on HR turbulence, non-linear dynamic, and maximum deceleration capacity of
R–R intervals, which provide very different and perhaps complementary information on HR dynamics compared to traditional
statistical methods (Mäkikallio et al., 2002; Bauer et al., 2006,
2008). Methods based on non-linear dynamics and HR turbulence
have provided somewhat better prognostic information than that
obtained by traditional methods (Bauer et al., 2006, 2008; Perkiömäki et al., 2008). In particular, decreased short-term fractal
scaling exponent by the DFA method (called DFA1 or α1), a measure of greater randomness in HR patterns, has turned out to be
a powerful non-linear index in risk stratiﬁcation, a more powerful prognostic tool than other HR variability indexes in post-AMI
populations (Huikuri et al., 2000; Mäkikallio et al., 2002). In the
DIAMOND-MI trial, reduced short-term fractal scaling exponent
identiﬁed post-AMI patients at a relative high risk of mortality
and was more strongly related to outcome than traditional time
and frequency domain measures (Huikuri et al., 2000). Moreover, reduced scaling exponent was related to both arrhythmic and
non-arrhythmic mortality (Huikuri et al., 2000). In another study
of consecutive patients with acute MI, both reduced short-term
fractal scaling exponent and power–law slope were independently
associated with recurrent non-fatal coronary events (Perkiömäki
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et al., 2008). Another measure of increased randomness of HR
patterns, such as the ratio of the axes of a Poincare plot ﬁtted to
the plot of each N–N interval vs. the next, also predicted mortality
in the CAST trial (Stein et al., 2005). Patients in the CAST were
at variable times post-MI but were selected for having signiﬁcant
ventricular arrhythmias.
One study in the era of modern therapy showed a very-low
incidence of severely depressed HR variability (SDNN <50 ms;
Erdogan et al., 2008). All patients in the study were treated
with direct percutaneous coronary angioplasty within 12 h of
their event. Although the 4-year survival was signiﬁcantly higher
in the low SDNN group, the positive predictive value was low,
suggesting that the predictive power of HR variability may not
be as high as earlier in patients receiving optimal medical and
revascularization therapy. However, results were based on traditional time-domain HR variability measures and there was no
report of results for non-linear measures or HR turbulence in this
population.

HR VARIABILITY AS A PREDICTOR OF ARRHYTHMIC
EVENTS/SUDDEN CARDIAC DEATH
The studies assessing the prognostic power of HR variability after
AMI have usually used all-cause mortality as the primary endpoint (see Table 1). Some studies, using various deﬁnitions of
arrhythmic events in their designs, have suggested that reduced
or altered HR variability may be speciﬁcally related to arrhythmic
events and sudden cardiac death. However, the clinical applicability of measurement of HR variability as a predictor of fatal
arrhythmic events was challenged in a randomized prophylactic
implantable cardioverter-deﬁbrillator (ICD) trial, the deﬁbrillator
in AMI trial (DYNAMIT) which, however, used reduced SDNN
combined with reduced left ventricular ejection fraction measured early (within 2 weeks) after AMI as an inclusion criterion
for the trial. The trial could not show any mortality beneﬁt from
ICD therapy in these presumably high risk patients (Hohnloser
et al., 2004). The more recent multicenter cardiac arrhythmias
and risk stratiﬁcation after myocardial infarction (CARISMA)
study showed that reduced HR variability measured relatively late
(6 weeks after AMI) rather than early after AMI, especially the
very-low frequency spectral component, was the most powerful
index among many other non-invasive risk markers in predicting
the fatal or near-fatal arrhythmic events diagnosed by implantable
arrhythmia devices (Huikuri et al., 2009). A further sub analysis of
the CARISMA and another recent similar study (Risk estimation
after infarction, non-invasive evaluation, REFINE) study conﬁrmed that HR variability and HR turbulence yield more powerful
prognostic information for arrhythmic events when measured late
(6–10 weeks after AMI) rather than early (within 2 weeks) after
AMI in the current treatment era (Huikuri et al., 2010). Thus
the lack of recovery from reduced autonomic function after AMI
was a stronger predictor of adverse events than decreased autonomic function early after AMI. A large study including more than
2000 post-AMI patients (FINGER-study) showed that reduced HR
variability and HR turbulence predicted sudden cardiac death better among those with a left ventricular ejection fraction >40%
than in those with ejection fraction <40% (Mäkikallio et al.,
2005).
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HR VARIABILITY AS A PREDICTOR OF NON-SUDDEN
CARDIAC DEATH
Observational studies using various end-points have shown that
reduced HR variability also predicts non-sudden cardiac death.
The largest study in this ﬁeld showed that reduced HR variability/turbulence is in fact a stronger predictor of non-sudden than
sudden cardiac death (Mäkikallio et al., 2005). In this study, the
majority of patients were treated according to current guidelines, i.e., with primary coronary interventions, beta-blocking
medication, and angiotensin converting enzyme inhibitors.
Considered together, the available data show that abnormal HR
variability, measured by various time and frequency domain measures, non-linear measures, and turbulence/deceleration capacity
measures from 24-h R–R interval recordings is a general risk
marker for common modes of cardiac death: arrhythmic, vascular,
and hemodynamic after AMI. HR variability/turbulence measured
early after AMI seems to provide more powerful information on
the risk of early non-sudden cardiac death, especially due to progressive heart failure. Because of remodeling of the arrhythmia
substrate after AMI, early measurement of HR variability to identify those at high risk of early mortality should likely be repeated
later in order to assess the true risk of fatal or near-fatal arrhythmia
events.
Often forgotten, however, in this focus on risk stratiﬁcation, is
the negative predictive value of HR variability measures. Patients
with normal HR variability measures, even if they are post-MI,
are at very-low risk of mortality. However, as has been found with
other non-invasive risk markers, the positive predictive accuracy
and sensitivity of abnormal HR variability for adverse outcomes
has remained low in most observational studies. The sensitivity,
speciﬁcity, and predictive values of HR variability in predicting
future events depend partly on deﬁning the cutoff points of abnormal HR variability measures. The cutoff points vary between the
studies and depend on the study populations, such as post-AMI
patients with and without heart failure, usage of beta-blocking
medication etc., which inﬂuence the HR variability measures, and
there is no universal consensus on the ideal cutoffs for different
measures. Age and presence of diabetes and even clinical depression are other factors inﬂuencing HR variability and should be
considered in deﬁning the cutoff of abnormal measures. HR variability has been combined with other risk markers in order to
improve risk stratiﬁcation in some studies. The problem with
combining various risk markers, however, is the overall loss of
sensitivity despite an improved positive predictive accuracy.
EFFECT OF INTERVENTIONS ON HR VARIABILITY
Finally, little is known about the effect of interventions on
HR variability in post-AMI patients and about whether interventions that are associated with improvements in HR variability are associated with better outcomes or vice versa. One
intervention, coronary artery bypass surgery (CABG) is associated
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